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LETTERS
Screening Blood 
Donors at Risk for 
Malaria: Reply to 
Hänscheid et al.
To the Editor: The letter to editor
by Hänscheid et al. addresses our sug-
gestion that polymerase chain reaction
(PCR) could serve as a reference test
for screening blood donations. At
present, PCR is the most sensitive and
specific method for parasite detection
in malaria-endemic areas. However,
additional measures should be taken
into account, such as serologic testing,
refining donor history, defining at-risk
locations, and delimiting malaria-
endemic areas. Therefore, we do not
suggest that only PCR should be used
as a reference method to exclude
blood donors at risk, but it could help
shorten the deferral period for blood
donor (currently 3 years after an
asymptomatic person leaves the
malaria-endemic area). PCR should be
accompanied by serologic tests and
the elimination of actual or possible
plasmodial infection in the blood
donor.
In our laboratory, we use the indi-
rect fluorescent antibody test (IFAT)
for antigens of the four plasmodia spe-
cies, in addition to PCR screening. At
present, we have analyzed a total of
531 blood samples (406 more than the
125 described in our previous letter to
the editor) from possible donors at risk
for malaria, and only the five
described in the letter were malaria
positive. Moreover, 40% (50 of 125)
of these sera were negative by IFAT
(unpub. data), a fact that indicates the
importance of having a complete
donor history and being certain of the
patient’s origin in the context of
malaria endemicity (i.e., several geo-
graphic areas without malaria trans-
mission in some Central and South
American countries could be excluded
as malaria-risk areas; these areas coin-
cide with sera negative by IFAT). 
On the other hand, with a standard
450-mL blood donation, parasitemias
<90 could test negative by PCR; but,
as previously described, this technique
should be accompanied by careful
questioning, serologic testing, and
eliminating parasites from the recipient
during blood processing and storage. 
We take for granted that, theoreti-
cally, any method would have to
detect a single parasite per unit of
blood to be safe and that little is
known about the frequency of low
parasitemias. In nature, and in accor-
dance with the parasitologic definition
of equilibrium between parasite and
host (defined over thousands or mil-
lions of years according to different
phylogenetic theories), one of the
main strategies for parasite survival is
sustained malaria transmission, which
allows low parasitemias to be ingested
by the anopheline vector (the amount
of blood ingested by the female
anopheline varies from 1.3 to 3.0 µL)
(1). In this way, the amount of blood
should have sufficient parasites to
continue the cycle inside the vector.
This fact explains the stability of
malaria transmission during dry sea-
sons. Plamodium falciparum infec-
tions can persist for at least 1 year in a
substantial proportion (10%) of the
host (2).
In two-thirds of the cases cited by
Mungai et al. (3), the donor-screening
process failed, illustrating the difficul-
ties in obtaining accurate travel and
immigration histories from donors. In
this paper, serologic tests were posi-
tive retrospectively in 98% of tested
donors, indicating that serologic tests
should be a useful screening technique
for malaria blood donors; 35%
showed parasitemia in blood smears, a
level that would have increased if the
blood had been analyzed on the day of
transfusion and not in retrospective
study (after the degradation or defor-
mation of the parasites or loss of stain-
ing of parasite chromatin). 
Moreover, two of the three cases
described by Slinger et al. (4) were in
blood donors positive by microscopy
or PCR (the other potential blood
donor was not available for follow-
up). These results show that parasites
could have been detected in these
cases, reflecting that all blood samples
had detectable parasitemias.
Serologic tests in Spain indicate
that approximately 50% of the referral
donations could be used in transfu-
sion, and travel histories should distin-
guish the specific destinations or the
level of malaria transmission in the
area. Most histories are based on the
wide areas of transmission listed in
travel guidelines. These data should
decrease the cost of testing per blood
donation when we add the value of the
blood donation to the real cost of
death prevented.
In conclusion, our initial results,
now accompanied by serologic results,
justify the exclusion criteria we first
reported (5). Screening tests for blood
donors (e.g., PCR) should be used as a
reference technique that could shorten
the deferral period for blood donors.
In all well-reported cases (complete
studies with follow-up) of transfusion-
associated malaria described in Can-
ada and the United States, PCR could
have detected the parasites in blood. 
Finally, the study of donors at risk
could serve as indirect surveillance for
asymptomatic infections and could
play an important role in detecting
autochthonous malaria transmission in
the United States (5) or Spain where
local anopheline vectors exist. An
additional benefit for parasite detec-
tion is that it would permit the donor
to be treated and locally acquired
malaria to be eliminated. The
Anopheline mosquito vectors of
malaria still exist in the United States
at levels sufficient to sustain malaria
transmission, and dozens of cases of
autochthonous malaria transmission
have been reported in the United
States over the past 15 years (6).
A. Benito and J.M. Rubio
Institute of Health Carlos III, Madrid, Spain
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Rickettsia 
aeschlimannii: 
A New Pathogenic 
Spotted Fever 
Group Rickettsia, 
South Africa
To the Editor: Spotted fever
group rickettsiae are increasingly rec-
ognized as agents of disease in resi-
dents of and tourists to South Africa
(1). To date, two species, Rickettsia
conorii and R. africae, which cause
Mediterranean spotted fever (MSF)
and African tick-bite fever (ATBF),
respectively, have been associated
with human disease in the region;
ATBF is more frequently associated
with travel (1). As different antibiotic
regimens are recommended for the
two syndromes, differentiating MSF
from ATBF is important. Increasing
evidence shows that the syndromes
can usually be differentiated through
clinical manifestations and epidemio-
logic characteristics (1).
We recently encountered a South
African patient who, on returning
from a hunting and fishing trip, dis-
covered a Rhipicephalus appendicula-
tus tick attached to his right thigh and
an eschar around the attachment site.
The patient was aware of the risk of
tick-transmitted disease; after remov-
ing the tick, immediately self-pre-
scribed doxycycline. No further
symptoms developed. However, as a
precaution, the patient went to a local
clinic, where a skin biopsy was taken
from the eschar. This sample, together
with the removed tick, was submitted
to our laboratory. DNA extracts, pre-
pared from an eschar biopsy and the
tick, were incorporated into a poly-
merase chain reaction (PCR) assay
specifically targeting a fragment of the
rickettsial ompA (2). Sequence analy-
sis of the amplification products
showed both to be identical and to
share >99% similarity with the ompA
of R. aeschlimannii, a species not pre-
viously associated with human dis-
ease. Unfortunately, blood samples
could not be collected at the time the
patients first had symptoms; thus,
investigation of a disseminated infec-
tion by PCR and serologic testing was
not possible.
Although genotypically indistin-
guishable organisms had previously
been detected in Hyalomma mar-
ginatum collected in Portugal and
Zimbabwe, R. aeschlimannii was first
characterized following its isolation
from H. marginatum ticks in Morocco
(3) and recently in Niger  (4). This
encounter was the first demonstration
of its presence in South Africa and in
Rhipicephalus ticks.
A lack of suitable clinical material
prevented full evaluation of the patho-
genic potential of R. aeschlimannii in
this patient and prompt antibiotic
intervention may have prevented evo-
lution of the syndrome. Nonetheless,
that R. aeschlimannii was transmitted
to the patient and established a local
infection leading to eschar formation
provides clear, albeit preliminary, evi-
dence of its virulence. Until further
cases are encountered, allowing better
characterization of the clinical mani-
festations associated with R. aeschli-
mannii infection and considering the
agent capable of inducing either MSF
or ATBF-like manifestations is cru-
cial; neither of these syndromes can be
associated with a specific causative
agent without microbiologic identifi-
cation. Our findings demonstrate that
Rickettsia species first encountered in
tick surveys are associated with
human disease, and we should not
assume that some Rickettsia species
not have a pathogenic potential.
Anne-Marié Pretorius* 
and Richard J. Birtles†
*University of the Free State, Bloemfontein,
South Africa and †University of Liverpool,
Liverpool, England
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Age as a Risk 
Factor for 
Cutaneous Human 
Anthrax: Evidence 
from Haiti, 
1973–1974
To the Editor: Few cases of
anthrax have been reported in chil-
dren, in part because most exposures
to Bacillus anthracis occur in work-
place settings. Questions about the
susceptibility of children to B. anthra-
cis infection were raised when cutane-
ous anthrax developed in a 7-month-